X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Magnesium sulfate injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia. It reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural junction.
Lead Product(s): Magnesium Sulfate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Magnesium Sulfate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alter Pharma group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
Oral paclitaxel, relative to intravenous paclitaxel, was associated with less neuropathy and was not associated with an increase in febrile neutropenia.
Lead Product(s): Paclitaxel,Encequidar,Dostarlimab
Therapeutic Area: Oncology Product Name: Taxol
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Quantum Leap Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
Athenex intends to use the net proceeds from the proposed offering to fund ongoing clinical development for its product candidates and for working capital and other general corporate purposes.
Lead Product(s): KUR-501,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: KUR-501
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 11, 2022
Details:
The publication of phase 3 data, which show that oral Taxol (paclitaxel) plus encequidar significantly improves tumor response in patients with metastatic breast cancer, compared to IV administration.
Lead Product(s): Paclitaxel,Encequidar,Dostarlimab
Therapeutic Area: Oncology Product Name: Taxol
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022
Details:
The agreement will support the expansion phase of the trial to further investigate the preliminary encouraging results of the KX-ORAX-011 Phase 1 clinical trial evaluating Oraxol (encequidar plus oral paclitaxel) in combination with pembrolizumab for certain NSCLC patients.
Lead Product(s): Paclitaxel,Encequidar,Pembrolizumab
Therapeutic Area: Oncology Product Name: Oraxol
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 16, 2022
Details:
KUR-501, is an autologous NKT cell CAR product that targets GD2, data demonstrate expansion of CAR-NKT cells post-transfer in all patients, and objective responses in patients with relapsed/refractory neuroblastoma.
Lead Product(s): GINAKIT Cells,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: KUR-501
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Encouraging data from interim update of the ANCHOR study support the promising efficacy and favorable safety profile of KUR-502 in heavily pretreated patients with hematological malignancies.
Lead Product(s): Allogeneic CD19 CAR-NKT Cells,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: KUR-502
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
Post hoc analysis of this subgroup of patients with hepatic impairment was conducted and showed a median survival rate of 18.9 months in patients treated with Oral Paclitaxel.
Lead Product(s): Paclitaxel,Encequidar
Therapeutic Area: Oncology Product Name: Oraxol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2021
Details:
Under the terms of the agreement, Athenex is granted worldwide rights to the development, manufacturing, and commercialization of allogeneic NKT products engineered via viral and non-viral means, and autologous T cell therapy products.
Lead Product(s): Allogeneic NKT Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 09, 2021
Details:
Updated data show continued favorable safety profile and encouraging anti-tumor activity in adult patients of in B-cell relapsed/refractory non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) treated with low doses of KUR-502 (Allogeneic CD19 CAR-NKT Cells).
Lead Product(s): CAR-NKT Cell,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: KUR-502
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
